Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
Timothy Iveson(University Hospital Southampton NHS Foundation Trust), James Paul(Cancer Research UK), Ioannis Boukovinas, Gerardo Rosati(Ospedale San Carlo), Andrea Harkin(Queen's University Belfast), Kentaro Yamazaki(Shizuoka Cancer Center), Mark Saunders(Manchester Academic Health Science Centre), Qian Shi(Mayo Clinic), Sara Lonardi(Istituto Oncologico Veneto), Niels Henrik Holländer(Zealand University Hospital Køge), Takayuki Yoshino(University of Tsukuba), Ioannis Sougklakos(University Hospital of Heraklion), Fang‐Shu Ou(Mayo Clinic), Jeffery P. Meyers(Mayo Clinic), Vassilis Georgoulias(Hellenic Oncology Research Group), Roberto Labianca(Ospedale Papa Giovanni XXIII), Takeharu Yamanaka(National Cancer Center Hospital East), Alberto F. Sobrero(Ospedale Policlinico San Martino), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 41
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k